While some firms have just a few stars, the lawyers of Finnegan Henderson Farabow Garrett & Dunner share equally in the spotlight. "It is probably the deepest group of IP experts of any firm I know," said a client. "It shows through the quality of the work." First tier in the patent and trade mark rankings, the firm was highly praised by legal commentators. Bilski v Kappos and i4i Limited Partnership v Microsoft were just two of the matters the firm handled in the last year, and both reached the Supreme Court. "Finnegan is as good as they come," said a client. "When an issue is tough, we usually bring it to Finnegan."
Some individual lawyers did earn nods - the highly respected Donald Dunner, and patent litigators J Michael Jakes, Michael Morin and Jeffrey Berkowitz. Of the three, a client said: "When I work with them, I feel like we're the only client, and that's the way I want it." Led by trade mark and copyright chair David Kelly, the firm's trade mark group was recommended by peers. "I've always thought of them, among the IP boutiques, as the leader," said one.
Finnegan rose to first tier this year in the biotechnology/life sciences rankings and dominates pharmaceutical litigation. Asked to recommend a firm that represents brand drug companies, a rival said: "Finnegan is at the top of my list." The firm successfully represented AstraZeneca, IPR and Shionogi in multidistrict litigation involving the $4.5 billion-a-year drug, Crestor. After depositions in Japan, Hawaii and Europe, and parallel litigation in Canada, Europe and Israel, Finnegan prevailed in the District of Delaware in preserving market exclusivity for the drug until 2016.